Slatopolsky E et al. |
Differential effects of 19-nor-1,25-(OH)(2)D(2) and 1alpha-hydroxyvitamin D(2) on calcium and phosphorus in normal and uremic rats. |
2002 |
Kidney Int. |
pmid:12234297
|
Bailie GR and Johnson CA |
Comparative review of the pharmacokinetics of vitamin D analogues. |
2002 Sep-Oct |
Semin Dial |
pmid:12358640
|
Coyne DW et al. |
Differential effects of acute administration of 19-Nor-1,25-dihydroxy-vitamin D2 and 1,25-dihydroxy-vitamin D3 on serum calcium and phosphorus in hemodialysis patients. |
2002 |
Am. J. Kidney Dis. |
pmid:12460048
|
Molnár I et al. |
19-nor-1alpha,25-dihydroxyvitamin D(2) (paricalcitol): effects on clonal proliferation, differentiation, and apoptosis in human leukemic cell lines. |
2003 |
J. Cancer Res. Clin. Oncol. |
pmid:12618899
|
Sprague SM et al. |
Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism. |
2003 |
Kidney Int. |
pmid:12631365
|
Martin CJ and Reams SM |
The renal dietitian's role in managing hyperphosphatemia and secondary hyperparathyroidism in dialysis patients: a national survey. |
2003 |
J Ren Nutr |
pmid:12671837
|
Slatopolsky E et al. |
Efficacy of 19-Nor-1,25-(OH)2D2 in the prevention and treatment of hyperparathyroid bone disease in experimental uremia. |
2003 |
Kidney Int. |
pmid:12753289
|
Cardús A et al. |
[Differential effect of vitamin D analogues on the proliferation of vascular smooth muscle cells]. |
2003 |
Nefrologia |
pmid:12778867
|
Kumagai T et al. |
Vitamin D2 analog 19-nor-1,25-dihydroxyvitamin D2: antitumor activity against leukemia, myeloma, and colon cancer cells. |
2003 |
J. Natl. Cancer Inst. |
pmid:12813173
|
Teng M et al. |
Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. |
2003 |
N. Engl. J. Med. |
pmid:12890843
|